Related Experiment Video
Updated: Aug 17, 2026

Conditional Knockdown of Gene Expression in Cancer Cell Lines to Study the Recruitment of Monocytes/Macrophages to the Tumor Microenvironment
Published on: November 23, 2017
Urokinase-type plasminogen activator system and breast cancer (Review)
Bo Han1, Misa Nakamura, Ichiro Mori
1Department of Pathology, Wakayama Medical University, Kimiidera 811-1, Wakayama 641-8509, Japan.
Abstract:
Malignant tumors have a capacity to degrade the extracellular matrix (ECM) by controlled proteolysis. One proteolytic system involved in these processes is the urokinase-type plasminogen activator (uPA) system, which consists of uPA, uPA receptor (uPAR) and uPA inhibitors 1 and 2 (PAI-1 and PAI-2). In the past two decades, study of the uPA system in human breast cancer has yielded valuable insights. Increased levels of uPA, PAI-1 and uPAR have been reported to be associated with poor prognosis in patients with breast cancer. Furthermore, uPA and PAI-1 may be new prognostic markers for axillary node-negative patients. To date, a growing body of evidence has suggested that uPA system promotes tumor metastasis by several different mechanisms, not just by breaking down the ECM. This article is focused on reviewing the current understanding of uPA system members as prognostic markers in breast cancer, and their cellular localization and tissue distribution. Correlations of the uPA system with other informative markers of breast cancer are also discussed.
Related Concept Videos
Clot Retraction and Fibrinolysis
Venous Thrombosis III: Interprofessional Care
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:

